Testing to inform PARP inhibitor cancer treatment

Testing to inform PARP inhibitor cancer treatment

A number of PARP inhibitors  are approved for reimbursement by the HSE which require testing to determine eligibility for treatment.

The following resources support that process:

• Guidance for medical oncologists on testing requirements by direct ordering to inform PARPi  treatment options
• Testing to inform PARP inhibitor cancer treatment : Patient Information Leaflet
• Niraparib/abiraterone (Akeega®) Therapy
• Olaparib (Tablet) Monotherapy
• Olaparib and Bevacizumab Therapy
• Talazoparib Therapy
• Link to direct ordering BRCA and/or HRD testing form